

## Financial Tear Sheet

### Corporate Profile

Bioverativ is a global biopharmaceutical company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development and commercialization of innovative therapies. Launched in 2017 following separation from Biogen Inc., Bioverativ builds upon a strong heritage of scientific innovation and is committed to actively working with the blood disorders community. The company's mission is to create progress for patients where they need it most, and its hemophilia therapies, when launched, represented the first major advancements in hemophilia treatment in more than two decades. For more information, visit [www.bioverativ.com](http://www.bioverativ.com) or follow @Bioverativ on Twitter.

### Primary IR Contact

Investor Relations  
**Phone:** 781-663-4360  
**E-mail:** [IR@bioverativ.com](mailto:IR@bioverativ.com)

### Stock Information

BIVV (Common Stock)  
 Exchange NASDAQ GS (US Dollar)  
 Price **\$60.07**  
 Change (%) ▲ 0.91 (1.54%)  
 Volume 764,494  
 52 Week Low \$40.00  
 Market Cap \$6,400,049,664  
 Rolling EPS 4.22  
 PE Ratio 14.0304  
 Shares Outstanding 108,182,043  
 Data as of 10/17/17 4:00 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.



### Recent News & Upcoming Events

10/02/17  
 Sangamo And Bioverativ Announce FDA Acceptance Of IND Application For ST-400 -- A Gene-Edited Cell Therapy Candidate -- To Treat Beta-Thalassemia

09/28/17  
 Bioverativ to Report Third Quarter 2017 Financial Results on October 26, 2017

09/06/17  
 Bioverativ and Bicycle Therapeutics Enter into Strategic Research Collaboration to Develop Therapies for Hemophilia and Sickle Cell Disease

Date	Title
10/27/17 8:00 a.m. ET	<b>Q3 2017 Bioverativ Inc Earnings Conference Call</b>

# SEC Filings

Filing Date	Form
09/14/17	8-K/A
08/31/17	4
08/10/17	4
08/08/17	4